These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33990705)

  • 41. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
    Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
    Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
    Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acute leukemia with cytogenetically cryptic FGFR1 rearrangement and lineage switch during therapy: A case report and literature review.
    McKeague SJ; O'Rourke K; Fanning S; Joy C; Throp D; Adams R; Harvey Y; Keng TB
    Am J Clin Pathol; 2024 Feb; 161(2):197-205. PubMed ID: 37855739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distinct immunophenotype of early T-cell progenitors in T lymphoblastic leukemia/lymphoma may predict FMS-like tyrosine kinase 3 mutations.
    Zaremba CM; Oliver D; Cavalier M; Fuda F; Karandikar NJ; Chen W
    Ann Diagn Pathol; 2012 Jan; 16(1):16-20. PubMed ID: 22050963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).
    Aljabry MS
    J Hematop; 2023 Mar; 16(1):27-31. PubMed ID: 38175368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
    Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
    Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Partial Response to Sorafenib in a Child With a Myeloid/Lymphoid Neoplasm, Eosinophilia, and a ZMYM2-FLT3 Fusion.
    Munthe-Kaas MC; Forthun RB; Brendehaug A; Eek AK; Høysæter T; Osnes LTN; Prescott T; Spetalen S; Hovland R
    J Pediatr Hematol Oncol; 2021 May; 43(4):e508-e511. PubMed ID: 32852395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
    Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
    Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.
    Vu HA; Xinh PT; Masuda M; Motoji T; Toyoda A; Sakaki Y; Tokunaga K; Sato Y
    Leukemia; 2006 Aug; 20(8):1414-21. PubMed ID: 16761019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21)].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):866-9. PubMed ID: 19698218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes.
    Choi JK; Xiao W; Chen X; Loghavi S; Elenitoba-Johnson KS; Naresh KN; Medeiros LJ; Czader M;
    Mod Pathol; 2024 May; 37(5):100466. PubMed ID: 38460674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of
    Baer C; Muehlbacher V; Kern W; Haferlach C; Haferlach T
    Haematologica; 2018 Aug; 103(8):e348-e350. PubMed ID: 29567772
    [No Abstract]   [Full Text] [Related]  

  • 58. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
    Lee BH; Williams IR; Anastasiadou E; Boulton CL; Joseph SW; Amaral SM; Curley DP; Duclos N; Huntly BJ; Fabbro D; Griffin JD; Gilliland DG
    Oncogene; 2005 Nov; 24(53):7882-92. PubMed ID: 16116483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
    Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
    Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Daver N; Strati P; Jabbour E; Kadia T; Luthra R; Wang S; Patel K; Ravandi F; Cortes J; Qin Dong X; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2013 Jan; 88(1):56-9. PubMed ID: 23115106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.